Peritoneal cancer treatment

Bibliography

• Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecological malignancy. Cancer 1989;63:364-7
   PubMed Web of Science ®Google Scholar
• Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545-50
   PubMed Web of Science ®Google Scholar
• Brucher BLm Piso P, Verwaal V, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC-overview and basics. Cancer Invest 2012;30:209-24
   PubMed Web of Science ®Google Scholar
• Zoetmulder FA, Verwaal VJ. Lessens learnt from clinical trials in peritoneal surface oncology: colorectal carcinomatosis. In: Gonzalez-Moleno A, editor, Advances in peritoneal surface oncology. Springer, Berlin, Heiderberg, New York; 2007. p. 99-104
   Google Scholar
• Jayne D. Molecular biology of peritoneal carcinomatosis. In: Ceelen WP, editor, Cancer treatment and research. Springer, New York, USA; 2007. p. 21-31
   Google Scholar
• Yonemura Y, Canbay E, Liu Y, et al. Trans-lymphatic metastasis in peritoneal dissemination. J Gastroint Dig Syst 2013;S12: P1-6
   Google Scholar
• Yonemura Y, editor. Atlas and principles of peritonectomy. NPO to support Peritoneal Surface Maligancy Treatment, Kobe, Oosaka, Kusatsu, Japan; 2012
   Google Scholar
• Sugarbaker PH, editor. Observation concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Peritoneal carcinomatosis: a multidisciplinary approach. Kluwar Academic Publisher, Boston, Dordrecht, London; 1997. p. 79-100
   Google Scholar
• Tsujimoto H, Takhashi T, Hagiwara A, et al. Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labeled cells. Br J Cancer 1995;71:468-72
   PubMed Web of Science ®Google Scholar
• Bettendorf U. Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics. Lymphology 1978;11:111-16
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Endou Y, Nojima N, et al. A possible role of cytokines in the formation of peritoneal dissemination. Int J Oncol 1997;11:349-58
   PubMed Web of Science ®Google Scholar
• Japanese Research Society for Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Clinical classificatrion. Jpn J Surg 1981;11:127-39
   PubMedGoogle Scholar
• Yonemura Y, Kawamura T, Bandou E, et al. The natural history of the free cancer cells in the peritoneal cavity. In: Gonzalez-Moleno A, editor, Advances in peritoneal surface oncology. Springer, Berlin, Heiderberg, New York; 2007. p. 11-23
   Google Scholar
• Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124-9
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Van Tinteren H, Van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739-46
   PubMed Web of Science ®Google Scholar
• Jaque P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58
   Web of Science ®Google Scholar
• Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43:15-25
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritonectomy procedure. Surg Oncol Clin N Am 2003;12:703-27
   PubMedGoogle Scholar
• Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intrapoeritoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol 2007;14:2289-99
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 2009;100:311-16
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Elnemr A, Endou Y, et al. Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection. Gastroenterol Res Pract 2012;2012:521487
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin A, Boot H, et al. 8-year follow-up of randomized trial:cytoreduction and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2633-5
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer J 2009;15(3):225-35
   PubMed Web of Science ®Google Scholar
• Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyerthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-6
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;15:3737-45
   Google Scholar
• Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyerthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-6
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Yu WS, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Sem Surg Oncol 2003;21:233-48
   PubMedGoogle Scholar
• Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol 2006;7:69-76
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;3:6237-42
   Google Scholar
• Cotte E, Glehen O, Mohammed F, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia and recurrent advanced ovarian cancer: prospective study of 81 patients. World J Surg 2007;31:1813-20
   PubMed Web of Science ®Google Scholar
• Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12
   PubMed Web of Science ®Google Scholar
• Yabusaki H, Nashimoto A, Tanaka O. Evaluation of TS-1 combined with cispatin for neoadjuvant chemotherapy in patients with advanced gastric cancer. Jpn J Cancer Chemother 2003;30:1933-40
   PubMedGoogle Scholar
• Matsuzaki T, Yashiro M, Kaizaki R, et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009;100:2402-10
   PubMed Web of Science ®Google Scholar
• Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction. Cancer 2008;113:945-55
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Mora JT, Carmingnani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112-22
   PubMed Web of Science ®Google Scholar
• Baron MA. Structure of intestinal peritoneum in man. Am J Anat 1941;69:439-97
   Google Scholar
• de Bree E, Tsiftsis DD. Experimental and pharmacologic studies in intraperitoneal chemotherapy from laboratory bench to bedside. In: Gonzalez-Moleno S, editor, Advances in peritoneal surface oncology. Springer, 2007. p. 53-73
   Google Scholar
• Miyamoto K, Shimada T, Sawamoto K, et al. Disposition kinetics of taxanes in peritoneal dissemination. Gastroenterol Res Pract 2012;2012:963403
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PHA, van der Vijgh WJ, et al. Direct diffusion of cis-diamminedichloroplatinum (II) in intraoperitoneal rat tumors after intraperitoenal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-4
   PubMed Web of Science ®Google Scholar
• Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2009;21:67-70
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Bandou E, Sawa T, et al. A new treatment by neoadjuvant intraperitoneal-systemic chemotherapy and peritonectomy for peritoneal dissemination from gastric cancer. Euro J Surg Oncol 2006;32:661-5
   PubMed Web of Science ®Google Scholar
• Franco J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemnic chemotherapy: a pooled analysis of north centralo cancer treatment group phase III trials N 9741 and N 9841. J Clin Oncol 2012;30:263-7
   PubMedGoogle Scholar
• Brucher B, Srojadinovic A, Bilchik A, et al. Patients at risk for peritoneal surface malignancy of colorectal cancer origin: the role of second look laparotomy. J Cancer 2013;4:262-9
   PubMed Web of Science ®Google Scholar
• Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg 2012;256:125-9
   PubMed Web of Science ®Google Scholar
• Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients withy advanced pseudomyxoma peritonei. Br J Cancer 2008;19:591-6
   Google Scholar
• Sugarbaker PH, Bijelic L, Chang D, et al. Neoadjuvant FOFLOX chemotherapy in34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010;102:576-81
   PubMed Web of Science ®Google Scholar
• Bijelic L, Kumar AS, Stuart OA, et al. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendiceal cancer: impact on perioperative outcome and short-term survival. Gastroenterol Res Pract 2012;2012:163284
   PubMed Web of Science ®Google Scholar
• Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreductionfor advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006;103:1070-6
   PubMed Web of Science ®Google Scholar
• Piso P, Slowik P, Popp F, et al. Safety of gastric resection during cytoreductive surgery and hyperthermiac intraperitoneal chemotherapyfor peritoneal carcinomatosis. Ann Surg Oncol 2009;16:2188-94
   PubMed Web of Science ®Google Scholar
• Evers DJ, Verwaal VJ. Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin. Br J Surg 2011;98:287-92
   PubMed Web of Science ®Google Scholar
• Elias D, Duchalais E, Dratigues P, et al. A new policy regarding ovarian resection in young women treated for peritoneal carcinomatosis. Ann Surg Oncol 2013;20:1837-42
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan D, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoredutive surgery and hyperthermiac intraperitoneal chemotherapy still be regarded as a highly morbidity procedure: a systematic review of morbidity and mortality. Ann Surg 2009;249:900-9075
   PubMed Web of Science ®Google Scholar
• Mizumoto A, Canbay E, Hirano M, et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract 2012;2012:836425
   PubMed Web of Science ®Google Scholar
• Smeenk RM, Verwaal VJ, Zoetmulder AN. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 2007;94:1408-14
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Rad Oncol 1984;10:791-6
   Web of Science ®Google Scholar
• Lepock JR. How do cells respond to their thermal environment. Int J Hyperthermia 2005;21:681-7
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Holden SA, Teicher BA. Hyperthermia and platinum complexes: time between treatment and synergy in vitro and in vivo. Int J Hyperthermia 1995;11:575-86
   PubMed Web of Science ®Google Scholar
• Barlogie B, Corry PM, Drewinko B. In vitro thermochemoterapy of human colon cancer cells with cis-dichlorodiamminplatinum (II) and mitomycin C. Cancer Res 1980;40:1165-8
   PubMed Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart QA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463-8
   PubMed Web of Science ®Google Scholar
• Urano M, Ling CC. Thermal enhabcement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 2002;18:307-15
   PubMed Web of Science ®Google Scholar
• Bijelic L, Sugarbaker PH, Stuart A. Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients. Gastroenterol Res Pract 2012;2012:827534
   PubMed Web of Science ®Google Scholar
• Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy. The tolerance of learning cuve. Cancer J 2009;15:196-9
   PubMed Web of Science ®Google Scholar
• DeBree E, Rosing D, Filis D, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol 2008;15:1183-92
   PubMed Web of Science ®Google Scholar
• Kondo T, Ueda K, Kano E. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells. Anticancer Res 1995;15:83-6
   PubMed Web of Science ®Google Scholar
• Cotte E, Passot G, Tod M, et al. Closed abdominal hyperthermic intraperitoneal chemotherapy with irinitecan and mitomycin C: a phase I study. Ann Surg Oncol 2011;18:2599-603
   PubMed Web of Science ®Google Scholar
• Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:4417-22
   Web of Science ®Google Scholar
• Plunkett W, Huang P, Xu Y, et al. Gemcitabine metabolism, mechanism of action, and self potentiation. Semin Oncol 1995;22(4 Suppl 11):3-10
   PubMed Web of Science ®Google Scholar
• Van Bree C, Beumaer C, Redemond HM, et al. Effectiveness of 2', 2 difluorodeoxyxitidine (gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 1999;15:549-56
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Stuyart A, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early date. Int J Surg Oncol 2011;2011:161862
   PubMedGoogle Scholar
• Bijelic L, Stuart A, Sugarbaker PH. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexede combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Prac 2012;2012:890450
   PubMed Web of Science ®Google Scholar
• Beaujard AC, Francoir Y, Glehen O, et al. Intraperitoneal chemohyperthermia with Mitomycin C in gastric cancer patients with peritoneal carcinomatosis. Anticancer Res 1999;19:1375-82
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart A, Sugarbajer PH. Using pharmacologic data to plan clinical treatment for patients with peritoneal surface maligancy. Curr Drug Discov Technol 2009;6:72-81
   PubMedGoogle Scholar
• Yan TD, Black D, Sugarbaker PH, et al. A systemic review and meta-analysis of the randomized controlled trial on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol 2007;14:2702-13
   PubMed Web of Science ®Google Scholar
• Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Databases Syst Rev 2006;(1):CD005340
   Google Scholar
• Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 2009;11:753-9
   PubMed Web of Science ®Google Scholar
• Leeuwen BLV, Graf W, Pahlman L, et al. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 2008;15:745-53
   PubMed Web of Science ®Google Scholar
• Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg 1991;78:57-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moreno S. Peritoneal surface oncology: a progress report. Eur J Surg Oncol 2006;32:593-696
   PubMed Web of Science ®Google Scholar
• Kuramoto M, Shimada S, Ikeshima S, et al. Etensive intraperitoneal peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric cancer. Ann Surg 2009;250:242-6
   PubMed Web of Science ®Google Scholar
• Yan QM, Bando E, Kawamura T, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan to Kagaku Ryoho 2006;33:1817-21
   PubMedGoogle Scholar
• Koh JL, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 2009;16:327-33
   PubMed Web of Science ®Google Scholar
• Spinelli P, Luini A, Pizzetti P, et al. Laparoscopy in staging and restaging of 95 patients with ovarian carcinoma. Tumori 1976;62:493-501
   PubMed Web of Science ®Google Scholar
• Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol 2006;32:625-7
   PubMed Web of Science ®Google Scholar
• Facchiano E, Scaringi S, Klanmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 2008;34:154-8
   PubMed Web of Science ®Google Scholar
• Thomas F, Ferron G, Gesson-Paute A, et al. Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy. Ann Surg Oncol 2008;15:3623-4
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Canbay E, Sako S, et al. Effects of laparosopic hyperthermic Intraperitoneal chemotherapy for peritoneal metastasis from gastric cancer. Cancer Clin Oncol 2014; In press
   Google Scholar
• Hirano M, Yonemura Y, Canbay E, et al. Laparoscopic Diagnosis and Laparoscopic Hyperthermic Intraoperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Detected by CT Examination. Gastroenterol Res Pract 2012;2012:741202
   PubMed Web of Science ®Google Scholar
• Kimura K, Tanaka S, Iwamoto M, et al. Safety of nanoparticle albimin-bound paclitaxel administration to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: four case reports. Oncol Lett 2013;6:881-4
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel with gemcitabine. N Engl J Med 2013;369(18):1691-703
   PubMed Web of Science ®Google Scholar
• Yardley DA. Nab-Paclitaxel mechanisms of action and delivery. J Control Release 2013;170:365-72
   PubMed Web of Science ®Google Scholar
• Smaglo BG, Hwang J. Continuum of care with anti-angiogenic therapiesin metastaticcolorectal cancer. J Gastroenteol Oncol 2013;4:299-307
   PubMedGoogle Scholar
• Ranieri G, Mammi M, Donato E, et al. Pazopanib a tyrosin kinase inhibitor with stronganti-angiogenic activity: a new treatmentfor metastatic soft tissue sarcoma. Crit Rev Oncol hematol 2013 ; pii:S1040-8428 (13)00189-3. doi: 10.1016/j. Critrevonc.2013.08.012
   Google Scholar
• Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedine in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different aschedules. J Clin Oncol 2009;27:4188-96
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117:1855-63
   PubMed Web of Science ®Google Scholar
• Cerruto CA, Brun EA, Chang D, et al. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 2006;130:1654-61
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastasis from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Scient World J 2013;2013:978394
   Google Scholar
• Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518-21
   PubMed Web of Science ®Google Scholar
• Yang XJ, Li Y, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol 2010;101:457-64
   PubMed Web of Science ®Google Scholar
• Canbay E, Ishibashi H, Sako S, et al. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg 2013;37(6):1271-6
   PubMed Web of Science ®Google Scholar
• Look M, Chang D, Sugarbaker PH. Long-term survival of cytoreductive surgery for advanced and recurrent epithelial ovarian cancer and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003;13:764-70
   PubMed Web of Science ®Google Scholar
• Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgerycombined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;15:3284-92
   Google Scholar
• Yan XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575-81
   PubMed Web of Science ®Google Scholar